Epithelial Ovarian Cancer Clinical Trials in Hackensack, New Jersey

3 studies are recruiting for epithelial ovarian cancer in Hackensack, New Jersey right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    John Theurer Cancer Center /ID# 275756, Hackensack, New Jersey
    Locations
    70 in total
    Run by
    AbbVie

    See if you can join NCT06890338 on ClinicalTrials.gov

  2. CT-95 in Advanced Cancers Associated With Mesothelin Expression

    This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with M…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Context Investigational Site, Hackensack, New Jersey
    Locations
    9 in total
    Run by
    Context Therapeutics Inc.

    See if you can join NCT06756035 on ClinicalTrials.gov

  3. A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

    This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. Th…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey
    Locations
    5 in total
    Run by
    Regeneron Pharmaceuticals

    See if you can join NCT06469281 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.